Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Mesoblast Ltd
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
No intraday reading yet this session.
Mesoblast Ltd has 1 disclosed supplier and 4 disclosed customers. Each one is named in an SEC filing, either Mesoblast Ltd’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our mesenchymal lineage cell product candidates for use in the conduct of our clinical trials, and we currently lack the internal resources and the capability to manufacture Ryoncil ® or any of our product candidates on a clinical or commercial scale. As a result, we currently depend on Lonza to manufacture Ryoncil ® and our mesenchymal lineage cell product candidates.”
FILING20-F0001345099-25-000067cik 0001345099
“Grünenthal arrangement In September 2019, Mesoblast entered into a strategic partnership with Grünenthal GmbH (Grünenthal) to develop and commercialize MPC-06-ID, the Company's Phase 3 allogeneic cell therapy candidate for the treatment of chronic low back pain due to degenerative disc disease in patients who have exhausted conservative treatment options. The agreement was amended by the parties in June 2021. Under the partnership, Grünenthal will have exclusive commercialization rights to MPC-06-ID for Europe and Latin America.”
FILING20-F0001345099-25-000067cik 0001345099
“The Development and Commercialization Agreement provides Tasly with exclusive rights to develop, manufacture and commercialize Revascor ® in China for the treatment or prevention of CHF and MPC-25-IC for the treatment or prevention of AMI. Tasly will fund all development, manufacturing and commercialization activities in China for Revascor ® and MPC-25-IC.”
FILING20-F0001345099-25-000067cik 0001345099
“In December 2017, we entered into a Patent License Agreement with TiGenix, now a wholly owned subsidiary of Takeda, which granted Takeda exclusive access to certain of our patents to support global commercialization of the adipose-derived MSC product Alofisel ® , previously known as Cx601, a product candidate of Takeda, for the local treatment of fistulae.”
FILING20-F0001345099-25-000067cik 0001345099
“With respect to the Second JCR Field, we are entitled to an approximately 50% profit share.”
FILING20-F0001345099-25-000067cik 0001345099
Watchlist prices, news filtered to it, and its next report on your desk.
MESO (Mesoblast Ltd) has 1 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: TAK +0.59%, in healthcare.